65 lines
3.6 KiB
Markdown
65 lines
3.6 KiB
Markdown
---
|
|
type: source
|
|
title: "Phase 2 RCT Protocol: Semaglutide for OUD Abstinence in Treatment-Refractory Patients (Grigson/Penn State, NCT06548490)"
|
|
author: "Grigson PS et al. / Penn State / Addiction Science & Clinical Practice"
|
|
url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12154142/
|
|
date: 2025
|
|
domain: health
|
|
secondary_domains: []
|
|
format: peer-reviewed study
|
|
status: unprocessed
|
|
priority: medium
|
|
tags: [glp-1, semaglutide, opioid-use-disorder, OUD, addiction, clinical-trial, Phase-2, VTA-dopamine, reward-circuit, NCT06548490]
|
|
---
|
|
|
|
## Content
|
|
|
|
Protocol publication for a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating semaglutide for opioid use disorder.
|
|
|
|
**Trial registration:** NCT06548490
|
|
|
|
**Design:**
|
|
- 200 participants with treatment-refractory OUD
|
|
- Outpatient population already receiving standard MOUD (buprenorphine or methadone)
|
|
- Three sites (NIH-funded)
|
|
- 12-week treatment period
|
|
- Double-blind, placebo-controlled
|
|
|
|
**Primary endpoint:** Opioid abstinence (confirmed by urine drug screens + self-report)
|
|
|
|
**Background:**
|
|
- Rodent models: GLP-1 RAs reduce opioid self-administration
|
|
- Residential OUD population: GLP-1 RAs decrease craving measures
|
|
- No completed controlled trial for outpatient OUD as of protocol publication (2025)
|
|
- Real-world data (Qeadan 2025): 40% lower opioid overdose rate in GLP-1 RA users
|
|
|
|
**Concerns noted:**
|
|
- Side effects: pancreatic cysts, pancreatic cancer risk, hypoglycemia, muscle cramps, cognitive slowing
|
|
- Adding GLP-1 to MOUD (buprenorphine/methadone) background — drug interaction considerations
|
|
- Population is treatment-refractory — higher difficulty achieving abstinence
|
|
|
|
**Current status:** Protocol published; trial ongoing; NO RESULTS AVAILABLE as of April 2026.
|
|
|
|
## Agent Notes
|
|
|
|
**Why this matters:** This is the only active well-powered Phase 2 RCT for GLP-1 in OUD. Its results (expected 2026-2027) will determine whether the Qeadan 2025 real-world signal holds up under controlled conditions. If the trial shows significant opioid abstinence improvement, the GLP-1 reward circuit mechanism claim becomes "likely" confidence. If null, the mechanism may be specific to food/alcohol reward circuits.
|
|
|
|
**What surprised me:** The trial is specifically for TREATMENT-REFRACTORY patients — those who are not achieving abstinence with buprenorphine or methadone. This is a high-need, hard-to-treat population. A positive result here would be especially meaningful.
|
|
|
|
**What I expected but didn't find:** Results. This is protocol-only.
|
|
|
|
**KB connections:**
|
|
- The pending results will directly inform whether the GLP-1 reward circuit claim can extend to opioids (currently experimental based on Qeadan observational + animal models)
|
|
- Active monitoring thread — check for results Q3/Q4 2026 or early 2027
|
|
|
|
**Extraction hints:**
|
|
- Do NOT extract as a claim — this is protocol only
|
|
- Archive as a monitoring item: "Phase 2 RCT underway, results expected 2026-2027"
|
|
- When results publish, this becomes a primary source for the OUD extension of the reward circuit claim
|
|
|
|
**Context:** Grigson is a leading addiction neuroscience researcher at Penn State. NIH-funded Phase 2 trial with OUD-focused design.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: GLP-1 reward circuit mechanism claim — OUD extension (pending)
|
|
WHY ARCHIVED: Protocol-only source. Monitor for results. This trial will resolve whether the GLP-1 mechanism extends to opioid abstinence in treatment-refractory patients. Do not extract now.
|
|
EXTRACTION HINT: No extraction yet. Flag as monitoring item. Revisit when trial results publish (expected 2026-2027).
|